Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)
Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion) for their fiscal year (FY) 2024 (April 2024 through March 2025). This would generate approximately SEK 360 M in net royalty to BioArctic. In Eisai’s FY2023 (April 2023 through March 2024), Leqembi sales reached JPY 4.3 billion, resulting in SEK 28.2 M in net royalty to BioArctic.Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-